VEECALVY Trademark

Trademark Overview


On Monday, March 4, 2024, a trademark application was filed for VEECALVY with the United States Patent and Trademark Office. The USPTO has given the VEECALVY trademark a serial number of 98431232. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, October 22, 2024. This trademark is owned by Pathalys Pharma, Inc.. The VEECALVY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biological preparations for treating hemodialysis patients; calcimimetics in the nature of pharmaceuticals that mimic the action of calcium on tissues; Pharmaceutical and biological preparations for use in nephrology and endocrinology; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing diseases, disorders, and conditions of the kidneys and glands; Pharmaceutical and biological preparations for treating and managing chronic kidney disease (CKD), end stage renal disease (ESRD), secondary hyperparathyroidism (SHPT), and conditions arising from complications of kidney disease and hemodialysis; Therapeutic agents for affecting calcium-sensing receptors on cells and managing calcium levels in the body
veecalvy

General Information


Serial Number98431232
Word MarkVEECALVY
Filing DateMonday, March 4, 2024
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, October 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 27, 2024

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations for treating hemodialysis patients; calcimimetics in the nature of pharmaceuticals that mimic the action of calcium on tissues; Pharmaceutical and biological preparations for use in nephrology and endocrinology; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing diseases, disorders, and conditions of the kidneys and glands; Pharmaceutical and biological preparations for treating and managing chronic kidney disease (CKD), end stage renal disease (ESRD), secondary hyperparathyroidism (SHPT), and conditions arising from complications of kidney disease and hemodialysis; Therapeutic agents for affecting calcium-sensing receptors on cells and managing calcium levels in the body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 4, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePathalys Pharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRaleigh, NC 27609

Party NamePathalys Pharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRaleigh, NC 27609

Trademark Events


Event DateEvent Description
Monday, March 4, 2024NEW APPLICATION ENTERED
Monday, March 4, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 19, 2024EXAMINERS AMENDMENT E-MAILED
Friday, July 19, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, July 19, 2024EXAMINER'S AMENDMENT ENTERED
Tuesday, July 16, 2024ASSIGNED TO EXAMINER
Friday, July 19, 2024EXAMINERS AMENDMENT -WRITTEN
Friday, July 19, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 7, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 27, 2024PUBLISHED FOR OPPOSITION
Tuesday, August 27, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 22, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT